China Oncology ›› 2017, Vol. 27 ›› Issue (10): 775-781.doi: 10.19401/j.cnki.1007-3639.2017.10.003
Previous Articles Next Articles
LU Weihui, WANG Cong, LI Chen, AI Zhilong
Online:
Published:
Contact:
Share article
Abstract: Background and purpose: Papillary thyroid cancer (PTC) is one of the most common carcinomas in humans. Galectin-3 is a multifunctional protein which regulates different process of tumorigenesis. Galectin-3 is widely distributed in various cancer tissues and the sera of cancer patients. The aim of this study was to explore the role of Galectin-3 in promoting PTC cells migration. Methods: Immunohistochemical analyses were performed on 40 PTC tissues and scores were calculated. PTC B-cpap cells were harvested after serum-free culture, and the extracellular and intracellular levels of Galectin-3 were measured. CCK-8 assay and wound healing assay were conducted after inhibition of Galectin-3 with two different methods. The transformation of cell morphology after inhibition of intracellular Galectin-3 was analyzed using immunofluorescence and confocal laser scanning. Results: Compared with those PTC patients without cervical lymph node metastasis, immunohistochemical scores of Galectin-3 were significantly higher in those with cervical lymph node metastases (P<0.05). The inhibition of extracellular and intracellular Galectin-3 attenuated the migration ability of cancer cells, but had different impact on cell proliferation. Transformation of cell morphology was also observed after inhibition of intracellular Galectin-3. Conclusion: Galectin-3 expression in tumor tissues was related to PTC metastasis. Inhibition of extracellular and intracellular galectin-3 could significantly decrease PTC cell migration.
Key words: Thyroid neoplasm, Galectin-3, Cell migration assay
LU Weihui, WANG Cong, LI Chen, et al. The role of Galectin-3 in promoting metastasis of papillary thyroid carcinoma[J]. China Oncology, 2017, 27(10): 775-781.
Recommend
Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks
URL: http://www.china-oncology.com/EN/10.19401/j.cnki.1007-3639.2017.10.003
http://www.china-oncology.com/EN/Y2017/V27/I10/775